TG Therapeutics (TGTX) Shares Down 6.2%

TG Therapeutics Inc (NASDAQ:TGTX)’s share price was down 6.2% during trading on Thursday . The company traded as low as $6.44 and last traded at $6.47. Approximately 1,077,167 shares traded hands during trading, a decline of 46% from the average daily volume of 2,009,883 shares. The stock had previously closed at $6.90.

A number of equities analysts recently commented on TGTX shares. Jefferies Financial Group reiterated a “buy” rating and set a $8.00 price target on shares of TG Therapeutics in a report on Wednesday, February 6th. BidaskClub upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, March 1st. ValuEngine cut TG Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 28th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of TG Therapeutics in a report on Friday, April 12th. Finally, Zacks Investment Research upgraded TG Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Wednesday, February 6th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. TG Therapeutics currently has an average rating of “Buy” and an average price target of $14.07.

The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.72 and a current ratio of 1.72.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.01. The business had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative return on equity of 309.17% and a negative net margin of 99,471.43%. As a group, equities analysts expect that TG Therapeutics Inc will post -1.61 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in TGTX. Bank of New York Mellon Corp raised its position in TG Therapeutics by 3.8% during the third quarter. Bank of New York Mellon Corp now owns 286,843 shares of the biopharmaceutical company’s stock valued at $1,606,000 after purchasing an additional 10,518 shares in the last quarter. Dimensional Fund Advisors LP acquired a new position in TG Therapeutics during the third quarter valued at approximately $361,000. JPMorgan Chase & Co. raised its position in TG Therapeutics by 7.0% during the third quarter. JPMorgan Chase & Co. now owns 304,497 shares of the biopharmaceutical company’s stock valued at $1,705,000 after purchasing an additional 19,957 shares in the last quarter. Vanguard Group Inc. raised its position in TG Therapeutics by 9.6% during the third quarter. Vanguard Group Inc. now owns 3,058,080 shares of the biopharmaceutical company’s stock valued at $17,125,000 after purchasing an additional 268,483 shares in the last quarter. Finally, Vanguard Group Inc raised its position in TG Therapeutics by 9.6% during the third quarter. Vanguard Group Inc now owns 3,058,080 shares of the biopharmaceutical company’s stock valued at $17,125,000 after purchasing an additional 268,483 shares in the last quarter. Institutional investors and hedge funds own 54.60% of the company’s stock.

WARNING: “TG Therapeutics (TGTX) Shares Down 6.2%” was posted by Rockland Register and is owned by of Rockland Register. If you are accessing this article on another domain, it was illegally copied and republished in violation of international trademark & copyright law. The legal version of this article can be accessed at https://rocklandregister.com/2019/06/01/tg-therapeutics-tgtx-shares-down-6-2.html.

TG Therapeutics Company Profile (NASDAQ:TGTX)

TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.

See Also: What Does Beta Mean In Stock Selection

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.